ClinicalTrials.gg
CompletedNCT06060665IDEALUpdated Jun 4, 2026

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

A Phase 3 interventional study of Seladelpar 10 mg and Placebo in Primary Biliary Cholangitis, sponsored by Gilead Sciences. Completed at 45 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
7th of 10
96 · median 126
Started
2023
with 1 other
Phase 3
5 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 9th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA).

The primary objective is to evaluate the effect of seladelpar treatment at Week 52 compared to placebo based on normalization of alkaline phosphatase (ALP) defined by a composite endpoint of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with an ALP value greater than ULN but less than 1.67× ULN.

03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • Primary Biliary Cholangitis (PBC)
  • PBC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Individuals must meet the following criteria to be eligible for study participation:

  1. Male or female with a diagnosis of primary biliary cholangitis (PBC) based on history.
  2. Ursodeoxycholic acid (UDCA) for the 12 months prior to screening (with stable dose for > 3 months prior to screening) OR intolerant to UDCA (last dose of UDCA > 3 months prior to screening).
  3. ALP > 1× and \< 1.67× ULN.
  4. Females of must use at least 1 barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.

Key Exclusion Criteria:

  1. Previous exposure to seladelpar (MBX-8025).
  2. A medical condition other than PBC that, in the Investigator's opinion, would preclude full participation in the study (eg, cancer) or confound its results.
  3. Advanced PBC as defined by the Rotterdam criteria.
  4. Laboratory parameters measured by the Central Laboratory at screening.
  5. hepatic decompensation.
  6. Other chronic liver diseases.
  7. Known history of (HIV) or positive antibody test at screening.
  8. Clinically important alcohol consumption, defined as more than 2 drink units per day in women and 3 drink units per day in men, or inability to quantify alcohol intake reliably.
  9. History of diagnosed or treated, active or within 2 years, or ongoing evaluation for malignancy; localized treatment of squamous or noninvasive basal cell skin cancers and cervical carcinoma in situ is allowed if appropriately treated prior to screening.
  10. History of drug abuse that would compromise the quality of the clinical study.
  11. Treatment with obeticholic acid or fibrates 6 weeks prior to screening.
  12. Treatment with colchicine, methotrexate, azathioprine, or long-term systemic within 2 months prior to screening.
  13. Initiation or dose adjustment of anti-pruritic drugs indicated for the treatment of pruritus within 1 month prior to screening.
  14. therapies within 6 months prior to screening.
  15. Other medications that affect liver or gastrointestinal functions, as well as the roux-en-y gastric bypass procedure, may be prohibited and should be discussed with the medical monitor on a case by-case basis.
  16. Treatment with any other therapy or device within 30 days or within halflives, whichever is longer, prior to screening.
  17. Pregnancy or plans to become pregnant, or breastfeeding.
  18. Any other condition(s) that would compromise the safety of the individual or compromise the quality of the clinical study, as judged by the investigator.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Seladelpar

    Participants will receive Seladelpar 10 mg one capsule daily for up to 52 weeks.

    Drug: Seladelpar 10 mg

  • Experimental
    Placebo

    Participants will receive placebo-to-match one capsule daily for up to 52 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Response defined as Alkaline phosphatase (ALP) ≤ 1.0× Upper Limit of Normal (ULN) AND ≥ 15% Decrease in ALP at Week 52.

    Time frame: 52 weeks

  2. Type, Frequency, and Severity of Treatment-emergent Adverse Events.

    Time frame: 52 weeks

Secondary outcomes

  1. Percentage of Participant Response Defined as ALP ≤ 1.0× ULN.

    Time frame: 52 weeks

  2. Percentage of Participant Response Defined as ALP ≤ 1.0× ULN AND ≥ 15% Decrease in ALP at 4 Weeks.

    Time frame: 4 weeks

  3. Percentage of Participant Response Defined as ALP ≤ 1.0× ULN AND ≥ 15% Decrease in ALP at 12 Weeks.

    Time frame: 12 weeks

  4. Percentage of Participant Response Defined as ALP ≤ 1.0× ULN AND ≥ 15% Decrease in ALP at 26 Weeks.

    Time frame: 26 weeks

  5. Percentage of Participant Response Defined as ALP ≤ 1.0× ULN AND ≥ 15% Decrease in ALP at 39 Weeks.

    Time frame: 39 weeks

  6. Absolute and Percent Change From Baseline in ALP.

    Time frame: 52 weeks

07

Study locations

45 sites
  • The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health
    Chandler, Arizona 85224, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • University of California (UC) Davis Medical Center
    Sacramento, California 95817, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • South Denver Gastroenterology
    Englewood, Colorado 80113, United States
  • Florida Research Institute
    Lakewood Rch, Florida 34211, United States
  • University of Miami - Schiff Center for Liver Diseases
    Miami, Florida 33136, United States
  • Gastro Health Research
    Miami, Florida 33176, United States
  • Covenant Metabolic Specialists, LLC
    Sarasota, Florida 33912, United States
  • Covenant Metabolic Specialists, LLC
    Tampa, Florida 33606, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Northwestern Medicine Clinical Research Unit (CRU)
    Chicago, Illinois 60611, United States
  • Tulane University Medical Center
    New Orleans, Louisiana 70112, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center - Baltimore, Maryland
    Baltimore, Maryland 21202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • New-York-Presbyterian Brooklyn Methodist Hospital
    Brooklyn, New York 11215, United States
  • Northwell Health Center for Liver Disease and Transplantation
    Manhasset, New York 11030, United States
  • New York University (NYU) Langone Medical Center
    New York, New York 10016, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • University of Rochester Medical Center - Strong Memorial Hospital
    Rochester, New York 14642, United States
  • Gastro Health Research
    Liberty Township, Ohio 45044, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Center for Liver Health
    Pittsburgh, Pennsylvania 15213, United States
  • OGI - Gastro One
    Cordova, Tennessee 38018, United States
  • Galen Hepatology
    Hixson, Tennessee 37343, United States
  • Gastrointestinal Associates of Northeast Tennessee, P.C.
    Johnson City, Tennessee 37604, United States
  • American Research Corporation - San Antonio, TX
    Austin, Texas 78757, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Liver Center of Texas
    Dallas, Texas 75234, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Soma Clinical Trials, LLC
    Denison, Texas 75020, United States
  • Baylor College of Medicine - Baylor Clinic
    Houston, Texas 77030, United States
  • Liver Associates of Texas, P.A.
    Houston, Texas 77030, United States
  • Bon Secours Liver Institute of Hampton Roads
    Richmond, Virginia 23226, United States
  • Velocity Clinical Research - Seattle
    Seattle, Washington 98105, United States
  • Stanford University
    Seattle, Washington 98195, United States
  • Centre de Recherche du Centre Hospitallier de I'Universite de Montreal (CRCHUM)
    Montreal, H2X3J4, Canada
  • (G.I.R.I.) GI Research Institute Foundation
    Vancouver, V6Z 2K5, Canada
08

References and documents

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in May 2026, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Sep 29, 2023
StartActual
Sep 5, 2023
Primary completionActual
May 6, 2026
CompletionActual
May 6, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06060665
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Sep 5, 2023
Primary completion
May 6, 2026
Completion
May 6, 2026
Last update
Jun 4, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion